Market Spotlight: Mantle Cell Lymphoma
Market Spotlight: Mantle Cell Lymphoma
$1,318.00
This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to 18,010 incident cases by 2026.
- It is estimated that the majority of diagnosed cases were male in 2017.
- The incidence of MCL is highest among older individuals aged 60+ years. Approved drugs in the MCL space focus on a wide variety of targets. The majority of these drugs are administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.
- The majority of industry-sponsored drugs in active clinical development for MCL are in Phase II. Therapies in active clinical development for MCL focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the MCL space comprise topline Phase II trial results for KTE-X19 and parsaclisib, topline Phase II/III trial results for TG-1303 and umbralisib, and topline Phase III trial results for Imbruvica and Venclexta.
- The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.5%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been five licensing and asset acquisition deals involving MCL drugs during 2014–19. The largest deal was the $391.5m strategic collaboration and licensing agreement between Innovent and Incyte in 2018 to develop and commercialize Incyte’s pemigatinib, itacitinib, and parsaclisib for hematology and oncology indications in China.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for MCL have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.
- The US has a substantial lead in the number of MCL clinical trials globally. France and Germany lead the major EU markets, while South Korea has the top spot in Asia.
- Johnson & Johnson has the highest number of completed clinical trials for MCL, with 13 trials. Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for MCL, followed by Celgene and Takeda.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
8 Symptoms
8 Risk factors
9 Diagnosis
10 TREATMENT
10 Targeted therapies
10 Chemotherapies
10 Steroids
11 Immunomodulators
11 Radiation therapy
11 Proteasome inhibitors
11 Stem cell transplantation
12 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Copiktra for MCL (July 25, 2019)
26 Copiktra for MCL (March 6, 2019)
27 Revlimid for MCL (February 27, 2019)
28 Zevalin for MCL (January 17, 2019)
29 Brukinsa for MCL (December 1, 2018)
31 Brukinsa for MCL (December 1, 2018)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Brukinsa Sprints To Accelerated Approval For MCL
35 Accord Gets EMA Support For Arsenic Trioxide
35 BeiGene Wins Breakthrough Status For Zanubrutinib With Assist From Chinese Data
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 Deals Shaping The Medical Industry, April 2019
38 PARENT PATENTS
39 REVENUE OPPORTUNITY
40 CLINICAL TRIAL LANDSCAPE
41 Sponsors by status
42 Sponsors by phase
44 BIBLIOGRAPHY
45 Prescription information
46 APPENDIX
LIST OF FIGURES
14 Figure 1: Global trends in incident cases of MCL, 2017–26
16 Figure 2: Global incident cases of MCL, by age, 2017
20 Figure 3: Overview of pipeline drugs for MCL in the US
20 Figure 4: Pipeline drugs for MCL, by company
21 Figure 5: Pipeline drugs for MCL, by drug type
21 Figure 6: Pipeline drugs for MCL, by classification
31 Figure 7: Brukinsa for MCL (December 1, 2018): Phase II – China
33 Figure 8: Zanubrutinib for MCL (December 1, 2018): Phase I/II – B-Cell Malignancies (Australia)
34 Figure 9: Key upcoming events in MCL
36 Figure 10: Probability of success in the MCL pipeline
37 Figure 11: Licensing and asset acquisition deals in MCL, 2014–19
38 Figure 12: Parent patents in MCL
40 Figure 13: Clinical trials in MCL
40 Figure 14: Top 10 drugs for clinical trials in MCL
41 Figure 15: Top 10 companies for clinical trials in MCL
41 Figure 16: Trial locations in MCL
42 Figure 17: MCL trials status
43 Figure 18: MCL trials sponsors, by phase
LIST OF TABLES
13 Table 1: Global incident cases of MCL, 2017–26
15 Table 2: Global incident cases of MCL, by gender, 2017
18 Table 3: Marketed drugs for MCL
22 Table 4: Pipeline drugs for MCL in the US
26 Table 5: Copiktra for MCL (July 25, 2019)
27 Table 6: Copiktra for MCL (March 6, 2019)
28 Table 7: Revlimid for MCL (February 27, 2019)
29 Table 8: Zevalin for MCL (January 17, 2019)
30 Table 9: Brukinsa for MCL (December 1, 2018)
32 Table 10: Brukinsa for MCL (December 1, 2018)
39 Table 11: Historical global sales, by drug ($m), 2014–18
39 Table 12: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the